Adil Daud, MD

Additional Websites

• Physician Referral Directory

---

Education

St. Francis De Sales College, Nagpur, India, 1980, HSC diploma in general science
Government Medical College, Nagpur, India, 1986, MBBS degree in Medicine

---

Professional Experience

• 1987-1990
  Postdoctoral Fellow, Laboratory of F. Merlin Bumpus, PhD and Ahsan Husain, PhD, Cleveland Clinic Foundation, Cleveland, OH
• 1990-1994
  Research Assistant Staff, Laboratory of Loren Field, PhD, Krannert Institute of Cardiology, Indiana University Medical Center, Indianapolis, IN
• 1994-1997
  Internship and Residency in Internal Medicine, Indiana University Medical Center, Indianapolis, IN
• 1997-2000
  Fellowship in Hematology/Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
• 2000-2001
  Clinical Attending Physician, Developmental Chemotherapy, Memorial Sloan-Kettering Cancer Center, New York, NY
• 2001-2005
  Assistant Professor, Cutaneous Oncology and GI Comprehensive Program, H. Lee Moffitt Cancer Center, Tampa, FL
• 2006-2008
  Associate Professor, Cutaneous Oncology, GI and Experimental Therapeutics Program, H Lee Moffitt Cancer Center, Tampa, FL
• 2006-2008
  Director, Moffitt Clinical Research Network
• 2008-2010
  Clinical Associate Professor and Director, Melanoma Clinical Research, University of California, San Francisco, CA
• 2010-present
  HS Clinical Professor of Medicine and Director, Melanoma Program, University of California, San Francisco, San Francisco CA

---

Honors & Awards

• 1986
  Honors in Pediatrics, Government Medical College, Nagpur, India
• 2000
  Young Investigator Award, American Society for Clinical Oncology for project “Regulation of mRNA stability by Elongation factor I.
• 2005-2007
  Clinical Trial Award: Highest Number of Patients Enrolled in clinical trials at Moffitt Cancer Center
• 2007-2010
  Best Doctors in America Award, Castle Connolly

---

Selected Publications

1. Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, Daud AI, McCalmont TH, Leboit PE, Ortiz-Urda S. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A. 2013 Mar 5; 110(10):4015-20.
   View on PubMed
2. Daud AI. Removing the unknown from the carcinoma of unknown primary. J Clin Oncol. 2013 Jan 10; 31(2):174-5.
   View on PubMed
3. Cha E, Daud A. Plasmid IL-12 electroporation in melanoma. Hum Vaccin Immunother. 2012 Nov 1; 8(11):1734-8.
   View on PubMed
4. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012 Nov; 367(18):1694-703.
   View on PubMed
5. Daud A, Soon C, Dummer R, Eggermont AM, Hwu WJ, Grob JJ, Garbe C, Hauschild A. Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma. Expert Opin Biol Ther. 2012 Aug; 12(8):1087-99.
   View on PubMed
6. Chong K, Daud A, Ortiz-Urda S, Arron ST. Cutting edge in medical management of cutaneous oncology. Semin Cutan Med Surg. 2012 Jun; 31(2):140-9.
   View on PubMed
7. Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A, Dilawari RA, Dimaio D, Guild V, Halpern AC, Hodi FS, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM. Melanoma. J Natl Compr Canc Netw. 2012 Mar; 10(3):366-400.
   View on PubMed
8. Daud A, Bastian BC. Beyond BRAF in Melanoma. Curr Top Microbiol Immunol. 2012; 355:99-117.
   View on PubMed
9. Daud AI, Krishnamurthi SS, Saleh MN, Gitlitz BJ, Borad MJ, Gold PJ, Chiorean EG, Springett GM, Abbas R, Agarwal S, Bardy-Bouxin N, Hsyu PH, Leip E, Turnbull K, Zacharchuk C, Messersmith WA. Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors. Clin Cancer Res. 2012 Feb 15; 18(4):1092-100.
   View on PubMed
10. Algazi AP, Weber JS, Andrews SC, Urbas P, Munster PN, DeConti RC, Hwang J, Sondak VK, Messina JL, McCalmont T, Daud AI. Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. Br J Cancer. 2012 Jan 3; 106(1):85-91.
    View on PubMed
11. Daud AI. BEAM trial: lighting the way ahead? J Clin Oncol. 2012 Jan 1; 30(1):6-7.
    View on PubMed
12. Munster PN, Daud AI. Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma. Expert Opin Investig Drugs. 2011 Nov; 20(11):1565-74.
    View on PubMed
13. Fishman MN, Thompson JA, Pennock GK, Gonzalez R, Diez LM, Daud AI, Weber JS, Huang BY, Tang S, Rhode PR, Wong HC. Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011 Dec 15; 17(24):7765-75.
    View on PubMed
14. Ahronowitz IZ, Daud AI, Leong SP, Shue EH, Bastian BC, McCalmont TH, Yu SS. An isolated Merkel cell carcinoma metastasis at a distant cutaneous site presenting as a second 'primary' tumor. J Cutan Pathol. 2011 Oct; 38(10):801-7.
    View on PubMed
15. Soon CW, Algazi AP, Cha EN, Webb EM, Daud AI. NRAS-mutant melanoma: response to chemotherapy. Arch Dermatol. 2011 May; 147(5):626-7.
    View on PubMed
16. Leong SP, Gershenwald JE, Soong SJ, Schadendorf D, Tarhini AA, Agarwala S, Hauschild A, Soon CW, Daud A, Kashani-Sabet M. Cutaneous melanoma: a model to study cancer metastasis. J Surg Oncol. 2011 May 1; 103(6):538-49.
    View on PubMed
17. Chow H, Jung A, Talbott J, Lin AM, Daud AI, Coakley FV. Tumor fistulization associated with targeted therapy: computed tomographic findings and clinical consequences. J Comput Assist Tomogr. 2011 Jan-Feb; 35(1):86-90.
    View on PubMed
18. DeConti RC, Algazi AP, Andrews S, Urbas P, Born O, Stoeckigt D, Floren L, Hwang J, Weber J, Sondak VK, Daud AI. Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma. Br J Cancer. 2010 Nov 9; 103(10):1548-53.
    View on PubMed
19. Finkelstein SE, Carey T, Fricke I, Yu D, Goetz D, Gratz M, Dunn M, Urbas P, Daud A, DeConti R, Antonia S, Gabrilovich D, Fishman M. Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma. J Immunother. 2010 Oct; 33(8):817-27.
    View on PubMed
20. Algazi AP, Soon CW, Daud AI. Treatment of cutaneous melanoma: current approaches and future prospects. Cancer Manag Res. 2010; 2:197-211.
    View on PubMed

View on UCSF Profiles